BBIO
BridgeBio Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$13.08B
P/E Ratio
—
EPS
$-3.74
Beta
0.97
52W High
$84.94
52W Low
$39.63
50-Day MA
$70.13
200-Day MA
$67.23
Dividend Yield
—
Profit Margin
-124.40%
Forward P/E
—
PEG Ratio
—
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Fundamentals
| Revenue (TTM) | $579.96M |
| Gross Profit (TTM) | $551.70M |
| EBITDA | $-498.88M |
| Operating Margin | -54.50% |
| Return on Equity | -1790.00% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $3.01 |
| Book Value | $-11.64 |
| Price-to-Book | 123.68 |
| Price-to-Sales (TTM) | 22.56 |
| EV/Revenue | 25.49 |
| EV/EBITDA | -9.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 66.80% |
| Shares Outstanding | $195.86M |
| Float | $152.80M |
| % Insiders | 3.90% |
| % Institutions | 103.19% |
Historical Volatility
HV 10-Day
25.32%
HV 20-Day
36.70%
HV 30-Day
36.75%
HV 60-Day
39.46%
HV Rank
25.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($102.71 target)
6
Strong Buy15
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026